Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of July 9, 2025 • 1:01 PM ET

Date/Time Source News Release
07/01/2025 06:30 AM EDT ACCESS Newswire There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate
06/18/2025 06:30 AM EDT ACCESS Newswire With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan
06/04/2025 06:55 AM EDT ACCESS Newswire NanoViricides Measles Drug Development Animal Study is Imminent
05/28/2025 06:30 AM EDT ACCESS Newswire NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025
05/22/2025 06:30 AM EDT ACCESS Newswire The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan
05/16/2025 06:30 AM EDT ACCESS Newswire NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu
05/14/2025 06:30 AM EDT ACCESS Newswire Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution
05/08/2025 06:30 AM EDT ACCESS Newswire Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo
05/05/2025 06:30 AM EDT Newsfile NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC
04/29/2025 06:30 AM EDT ACCESS Newswire Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It
Page

Additional News

As of July 9, 2025 • 1:01 PM ET

Date/Time Source News Release
06/18/2025 09:12 AM EDT InvestorWire InvestorNewsBreaks - NanoViricides (NYSE American: NNVC) Highlights NV-387 as Broad-Spectrum Antiviral Candidate for COVID and Bird Flu Preparedness 
06/04/2025 10:35 AM EDT BioMedWire BioMedNewsBreaks - NanoViricides (NYSE American: NNVC) Advances Measles Drug Program Amid Rising Global Outbreaks 
05/28/2025 09:15 AM EDT BioMedWire BioMedNewsBreaks - NanoViricides (NYSE American: NNVC) to Present Breakthrough Antiviral Platform at BIO International Convention
05/22/2025 09:15 AM EDT InvestorWire InvestorNewsBreaks - NanoViricides (NYSE American: NNVC) Comments on FDA COVID Booster Policy, Highlights Antiviral Strategy
05/16/2025 09:25 AM EDT InvestorWire InvestorNewsBreaks - NanoViricides (NYSE American: NNVC) Advances NV-387 Antiviral Program, Prepares for Multiple Phase II Trials
05/16/2025 06:48 AM EDT SeekingAlpha NanoViricides GAAP EPS of -$0.14
05/14/2025 10:55 AM EDT BioMedWire BioMedNewsBreaks - NanoViricides (NYSE American: NNVC) Advances NV-387 Antiviral as Measles and MPox Resurge Globally 
05/08/2025 09:45 AM EDT BioMedWire BioMedNewsBreaks - NanoViricides (NYSE American: NNVC) Clears Ethics Review for Phase II Mpox Trial in DRC 
05/05/2025 09:15 AM EDT InvestorBrandNetwork BioMedNewsBreaks - NanoViricides (NYSE American: NNVC) to Present at D. Boral Capital Inaugural Global Conference 
04/29/2025 10:18 AM EDT InvestorBrandNetwork BioMedNewsBreaks - NanoViricides (NYSE American: NNVC) Advances Measles Drug Development with Broad-Spectrum Antiviral NV-387 
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.